浅谈静脉留置针的临床应用和护理

目的:体会静脉留置针的临床应用和护理、总结经验.方法:观察48例住院患者静脉留置针的使用方法,日常护理及并发症的处理.结果:提高了护理工作的效率,减轻了病人穿刺时的痛苦.结论:护理人员除要熟练掌握操作规程、严格无菌操作外,还应严密观察病人的病情变化.要有高度责任心,从而减轻病人的痛苦.     

The diagnostic value of image guided percutaneous fine needle aspiration biopsy in equivocal mediastinal masses

Background and aims The aim of this study was to assess the diagnostic value of image guided percutaneous fine needle aspiration (FNA) biopsy in equivocal mediastinal masses.Patients Sixty-six patients with an equivocal mediastinal mass who underwent FNA biopsy between 1993 and 2003 were eligible for final analysis. The cytological and definitive diagnosis of masses were grouped as primary 22 (33%)−30 (46%) and secondary (metastatic) neoplasms 18 (27%)−18 (27%) and nonneoplastic lesions 20 (30%)−18 (%27) respectively.Results The diagnostic accuracy (%95 C.I.) of FNA biopsy for primary mediastinal neoplasms, secondary neoplasms and nonneoplastic lesions were found to be 93.3 (83.8–98.2)%, 100 (95.1–100)%, 93.3 (83.8–98.2)%, respectively.Conclusion Image guided percutaneous FNA biopsy is a safe and highly accurate diagnostic method for equivocal mediastinal masses.     

伽玛刀治疗垂体腺瘤126例的临床分析

目的 评价伽玛刀治疗垂体腺瘤的疗效和并发症.方法 对2000年8月至2005年12月间伽玛刀治疗垂体腺瘤并有完整临床资料.病人年龄15～76岁,肿瘤最大径<10mm 68例、10～20mm 56例、>20mm 2例,伽玛刀治疗剂处方量为15～30Gy、50%～65%等剂量曲线.结果 随访1～6年,肿瘤消失75例,肿瘤缩小28例,肿瘤无变化15例,肿瘤继续增大8例.肿瘤生长控制率93.6%(118/126);激素水平恢复正常率63%(49/78),垂体功能低下发生率为15%,因肿瘤复发或激素水平未恢复再行肿瘤切除术5例.结论 伽玛刀治疗垂体腺瘤,能控制垂体腺瘤肿瘤生长,可恢复垂体内分泌功能异常改变.     

Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients

Background and aims Radiofrequency-ablation (RFA) is increasingly used for destruction of unresectable primary and secondary liver tumors. We report our experience in the use of RFA for the management of unresectable hepatic malignancies. Patients and methods Between February 2000 and December 2004 we have undertaken 120 RFA procedures to ablate 426 unresectable primary or metastatic liver tumors in 88 patients. RFA was performed via laparotomy (n=68), laparoscopy (n=9) or a percutaneous approach (n=43). Primary liver cancer was treated in seven patients (8%) and metastatic liver tumors were treated in 81 patients (92%). All patients were followed to assess complications, treatment response and recurrence of malignant disease. Results Procedure-related complication rate was low (3.4%). During a mean follow-up of 21.2 months, 15 patients had local tumor progression (17%), 21 patients (23,9%) had new malignant disease and 27 patients (30.7%) died from intervention-unrelated complications of their malignant disease. Additional liver lesions were identified in 27 (35%) of 77 cases by intraoperative ultrasound. Thirty-six patients received simultaneous resection and RFA. Conclusion RFA is a safe, well-tolerated and effective treatment for patients with unresectable primary and secondary liver malignancies.     

Renal allograft immunosuppression

We have investigated the impact of triple drug immunosuppression on the occurrence of early inflammatory episodes, as detected by fine needle aspiration biopsy, and of episodes of clinical rejection during the immediate postoperative period. The prospective component of this study includes 128 consecutive first cadaveric renal transplant recipients receiving triple drug treatment consisting of azathioprine (Aza), cyclosporin (CyA) and methylprednisolone (MP). For controls we have used three historical groups: one immunosuppressed with Aza and MP (group A), another with CyA monotherapy (group B), and the third with CyA together with MP (group C) in equivalent drug dosages. On the average, 0.8 episodes of inflammation per patient were recorded during the immediate postoperative period of 30 days with triple drug treatment. This was significantly less than the 1.3 episodes in patients receiving Aza and MP (P<0.01), the 1.7 episodes in patients on CyA monotherapy (P<0.001), or the 1.6 episodes in patients receiving CyA together with MP (P<0.001). Although the first episode of inflammation commenced concurrently in each group and the peak intensity of inflammation was the same, the mean duration of inflammation was significantly shorter-2.7 days-under triple drug treatment than the 7.8–11.7 days for controls (P<0.001). The frequency of rejection episodes under triple treatment was also significantly lower-0.2 per patient-than the 0.8 per patient in controls (P<0.001). The first rejection episode occurred later in the triple drug treatment group-on the average, on day 15.2-than in the historical controls (on days 7.7–11.7). There was, however, no difference in the duration of rejection. There were no differences in patient survival between the four groups. Graft survival was 97% at 10 weeks for triple drug-treated recipients and 79%, 68%, and 87% for first grafts in groups A, B, and C, respectively. Disregarding a minor demographic bias for the triple drugtreated group with respect to preformed antibodies and preoperative dialysis treatment, the study suggests that the triple drug protocol, in the short run, is superior to any conceivable double drug combination or CyA monotherapy.     

针吸细胞学诊断乳腺肿块的体会

在欧美,乳腺肿块针吸细胞学诊断于70年代就已得到了成功的应用。近年来国内的一些研究也证实其实用价值。为了进一步提高乳腺细胞学诊断水平,现将我院针吸细胞学诊断乳腺肿块281例中由病理证实的118例进行总结分析。1 材料与方法1.1 临床资料:1986年12月～1990年2月采用针吸细胞学检查诊断乳腺肿块281例,其中118例施行手术并获得病理组织学的证实。细胞学诊断以原始报告为准。女     

A rat model of monitoring liver allograft rejection

Rat models are often used to study liver allograft rejection. We have established a model for rat liver allograft rejection, monitored by fine needle aspiration biopsy (FNAB), in the strain combination PVG-to-BN with a mean survival time of 37 ± 20 days. In this model, we observed acute rejection with an intense peak of lymphoid blasts and lymphocyte-dominated inflammation in the FNAB [9.1 ± 3.0 corrected increment units (CIU)], and an eventual increase in macrophages (up to 4.2 ± 4.4 CIU), together with fibrosis and parenchymal necrosis in the graft. Markers of immune activation, such as an increase in IL-2-receptor (from 1 % ± 2 % to 21 % ± 13 %) and class II (from 20 % ± 9 % to 43 % ± 13 %) expressing lymphoid cells and induction of ICAM-1 in the graft, were consistent with the overall cellular response. The FNAB correlated well with parallel graft histology. In this rat model, the atraumatic monitoring makes a close follow-up possible without having to sacrifice the experimental animals. This saves work, animals, and costs in the study of liver rejection. Received: 2 July 1996 Accepted: 28 October 1996     

CT导引下胸部病变穿刺活检影响诊断正确率因素分析

目的 :探讨影响CT导引下胸部病变穿刺活检诊断正确率的因素。方法 :复习有手术病理、临床和影像学随访的胸部病变CT导引下穿刺活检 2 4 4例 ,依据手术病理、治疗反应及临床随访结果对活检病灶作出最终诊断 ,观察因素包括患者相关因素 (性别、年龄、有无肺气肿 )、病灶相关因素 (病灶大小、位置、有无空腔及病灶深度 )和操作相关因素 (患者的体位 )。结果 :胸部病变CT导引下穿刺活检诊断正确率为 82 .4 % ( 2 0 1 /2 4 4)。活检诊断正确率与病灶大小有关 ,诊断正确组和非正确组病灶大小分别为 3 .97± 1 .80cm和 3 .1 1± 1 .4 4cm(P <0 .0 5 )。患者性别、年龄、有无肺气肿、病灶位置、深度、有无空腔及患者体位对穿刺活检诊断正确率的影响无统计学意义。结论 :病灶大小是影响CT导引下胸部病变穿刺活检诊断正确率的主要因素